MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date

Tuesday, September 24, 2019

1:45pm-3:15pm
Lip movement contribution in speech production of persons with Parkinson’s Disease

P. Upadhyay, S. Gudwani, K. Sharma, R. Sagar, R. Dhamija, S. Kumaran (New Delhi, India)

Parkinsonisms and Parkinson-Plus  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Liquid Levodopa/Carbidopa – An underutilized, cost effective treatment of advanced Parkinson’s disease in the developing world

A. Panwar, N. Sawal (Chandigarh, India)

Parkinsonisms and Parkinson-Plus  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Local beta band synchronization predicts clinically-selected deep brain stimulation contact in Parkinson’s disease patients

W. Lipski, HJ. Park, A. Jorge, A. Kent, Y. Pathak, RM. Richardson (Pittsburgh, PA, USA)

Neurophysiology  ·  Les Muses Terrace, Level 3
1:45pm-3:15pm
Long-term adherence with wearing a multi-sensor watch in the Personalized Parkinson Project

L. Evers, R. Kapur, T. V.D. Zande, M. Meinders, B. Bloem, W. Marks, JR. (Nijmegen, Netherlands)

Parkinsonisms and Parkinson-Plus  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease

M. Fabbri, P. Chatkaew, C. Artusi, A. Romagnolo, M. Rizzone, M. Zibetti, L. Lopiano (Turin, Italy)

Parkinsonisms and Parkinson-Plus  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Long-Term Effects of LPS and Alcohol in Rats: A Model of Neuro-Degenerative Disease

M. Schiess, M. Doursout, J. Campo, Z. Peng, A. Sundaresan, S. Umar (Lawrence, KS, USA)

Parkinsonisms and Parkinson-Plus  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Long-term treatment of cervical dystonia with abobotulinumtoxinA

A. Jochim, T. Meindl, T. Mantel, S. Zwirner, F. Castrop, B. Haslinger (Munich, Germany)

Dystonia  ·  Les Muses Terrace, Level 3
1:45pm-3:15pm
Longitudinal assessment of genetic determinants of cognitive decline in Parkinson’s disease

M. Bakeberg, A. Jefferson, M. Byrnes, S. Ghosh, F. Mastaglia, R. Stell, J. Kenna, S. Walters, M. Hoes, A. Ford, R. Anderton (Nedlands, Australia)

Parkinsonisms and Parkinson-Plus  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Longitudinal progression of spatiotemporal parameters of turning in idiopathic Parkinson’s disease patients with Freezing of Gait

L. Pillai, A. Glover, T. Virmani (Little Rock, AR, USA)

Parkinsonisms and Parkinson-Plus  ·  Agora 3 West, Level 3
1:45pm-3:15pm
Longstanding cervical dystonia followed by parkinsonism – coincidence, risk factor or syndromic association?

B. Balint, F. Gövert, A. Latorre, E. Mulroy, R. Erro, A. Batla, T. Warner, K. Bhatia (London, United Kingdom)

Parkinsonisms and Parkinson-Plus  ·  Agora 3 West, Level 3
  • «Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 69
  • Next Page»

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley